Abstract
Evaluation of new technologies requires rigorous methods to provide unbiased estimates of the performance and so inform future clinical practice. We review evidence on DNA cytometry reported earlier in this journal and point to the standards for reporting of diagnostic accuracy as a metric against which this article can be evaluated. The cross-sectional nature of the data and incomplete reporting limit the clinical utility of the study. With application of improved reporting standards for diagnostic tests and improved design and evaluation of new technologies for screening, we may better inform practices to improve clinical outcomes and population health.
| Original language | English |
|---|---|
| Pages (from-to) | 6971-6972 |
| Number of pages | 2 |
| Journal | Clinical Cancer Research |
| Volume | 17 |
| Issue number | 22 |
| DOIs | |
| State | Published - Nov 15 2011 |